Christopher Ruel
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
Papers in
- Oncology 30
- Cancer Treatment and Pharmacology 12
- Cancer Immunotherapy and Biomarkers 10
- HER2/EGFR in Cancer Research 6
- CAR-T cell therapy research 6
- Peptidase Inhibition and Analysis 5
-
- Protein Degradation and Inhibitors 5
- Co-authors
- Paul Frankel (32 shared papers)David R. Gandara (5 shared papers)Przemyslaw Twardowski (7 shared papers)Primo N. Lara (6 shared papers)Marianna Koczywas (5 shared papers)Igor Espinoza‐Delgado (1 shared paper)Suresh S. Ramalingam (1 shared paper)Chandra P. Belani (1 shared paper)
- Journals
- Journal of Clinical Oncology (13 papers)Cancer (4 papers)The Oncologist (3 papers)Blood (3 papers)Clinical Cancer Research (2 papers)
- Partner nations
- United States
In The Last Decade
Christopher Ruel
43 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 69
- Oncology 536
- Pulmonary and Respiratory Medicine 309
- Cancer Research 131
- Hematology 93
- Immunology 154
Countries citing papers authored by Christopher Ruel
This map shows the geographic impact of Christopher Ruel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Ruel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Ruel more than expected).
Fields of papers citing papers by Christopher Ruel
This network shows the impact of papers produced by Christopher Ruel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Ruel. The network helps show where Christopher Ruel may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher Ruel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 133 | |
| 2 | 2004 | 84 | |
| 3 | 2010 | 66 | |
| 4 | 2011 | 62 | |
| 5 | 2021 | 61 | |
| 6 | 2020 | 60 | |
| 7 | 2013 | 59 | |
| 8 | 2015 | 55 | |
| 9 | 2018 | 54 | |
| 10 | Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. | 2009 | 44 |
| 11 | 2015 | 36 | |
| 12 | 2007 | 32 | |
| 13 | 2015 | 26 | |
| 14 | 2006 | 26 | |
| 15 | 2019 | 25 | |
| 16 | 2008 | 24 | |
| 17 | 2011 | 22 | |
| 18 | 2014 | 21 | |
| 19 | 2008 | 17 | |
| 20 | 2009 | 17 |
About Christopher Ruel
Christopher Ruel is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Hematology, having authored 47 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (12 papers), Cancer Immunotherapy and Biomarkers (10 papers), HER2/EGFR in Cancer Research (6 papers), Multiple Myeloma Research and Treatments (6 papers), CAR-T cell therapy research (6 papers), Advanced Breast Cancer Therapies (6 papers), Protein Degradation and Inhibitors (5 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Oncology (536 citations), Pulmonary and Respiratory Medicine (309 citations), Cancer Research (131 citations), Hematology (93 citations) and Immunology (154 citations). Christopher Ruel has collaborated with scholars based in United States. Frequent co-authors include Paul Frankel, David R. Gandara, Przemyslaw Twardowski, Primo N. Lara, Marianna Koczywas, Igor Espinoza‐Delgado, Suresh S. Ramalingam, Chandra P. Belani, Barbara J. Gitlitz and David R. Gandara. Their work appears in journals such as Journal of Clinical Oncology, Cancer, The Oncologist, Blood and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.